Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua F Zeidner

Showing results (1-10 of 80) with videos related to

Pageof 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2020
Differentiating the Differentiation Syndrome Associated with IDH Inhibitors in AMLJoshua F Zeidner
Therapeutic Advances in Hematology|July 28, 2022
The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?Anson Snow, Joshua F Zeidner
The American Journal of Medicine|July 9, 2010
Painless jaundiceJoshua F Zeidner, Emily Sydnor
Current Cancer Drug Targets|July 25, 2020
Acute Myeloid Leukemia: Changing Treatment Paradigms and Novel Agents in DevelopmentHeiko Konig, Joshua F Zeidner
Expert Opinion on Emerging Drugs|July 6, 2021
Emerging therapies for AML with myelodysplasia-related changes: slowly but surely moving the needleDavis F Phillips, Joshua F Zeidner
Cancer|April 7, 2025
A second look at the status quo for secondary acute myeloid leukemia after hypomethylating agentsDaniel T Peters, Joshua F Zeidner
Blood|May 24, 2014
Reason for CPXcitement in AMLJoshua F Zeidner, Judith E Karp
Current Drug Targets|March 5, 2015
Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML)Joshua F Zeidner, Matthew C Foster
Leukemia Research|November 3, 2015
Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemiaJoshua F Zeidner, Judith E Karp
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2022
TP53 or Not TP53: That Is the QuestionSteven D Green, Joshua F Zeidner
Pageof 8

Showing results (1-10 of 80) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2020
Differentiating the Differentiation Syndrome Associated with IDH Inhibitors in AMLJoshua F Zeidner
Therapeutic Advances in Hematology|July 28, 2022
The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?Anson Snow, Joshua F Zeidner
The American Journal of Medicine|July 9, 2010
Painless jaundiceJoshua F Zeidner, Emily Sydnor
Current Cancer Drug Targets|July 25, 2020
Acute Myeloid Leukemia: Changing Treatment Paradigms and Novel Agents in DevelopmentHeiko Konig, Joshua F Zeidner
Expert Opinion on Emerging Drugs|July 6, 2021
Emerging therapies for AML with myelodysplasia-related changes: slowly but surely moving the needleDavis F Phillips, Joshua F Zeidner
Cancer|April 7, 2025
A second look at the status quo for secondary acute myeloid leukemia after hypomethylating agentsDaniel T Peters, Joshua F Zeidner
Blood|May 24, 2014
Reason for CPXcitement in AMLJoshua F Zeidner, Judith E Karp
Current Drug Targets|March 5, 2015
Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML)Joshua F Zeidner, Matthew C Foster
Leukemia Research|November 3, 2015
Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemiaJoshua F Zeidner, Judith E Karp
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2022
TP53 or Not TP53: That Is the QuestionSteven D Green, Joshua F Zeidner
Pageof 8